CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Safety and efficacy of twice daily versus every 8 hour telaprevir with Peginterfepon/Ribavirin (PR) in patients with cirrhosis
DOI 10.1055/s-0033-1352748
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Buggisch, YJ Horsmans, RS Brown, M Buti, K Agarwal, W Sievert, E Janczewska, C Hezode, M Rizzetto, R Parana, S De Meyer, R De Masi, D Luo, J Witek, S Zeuzem
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Non-inferior efficacy of telaprevir (TVR) twice-daily (bid) versus every 8 hours (q8h), in combination with peginterferon/ribavirin (PR) in treatment-naïve patients, has been established across a range of patient baseline characteristics. Here we describe detailed results of TVR bid or q8h across fibrosis/cirrhosis stages. Methods: OPTIMIZE was a randomized, open-label, multicenter, Phase III trial in treatmen…
Zitieren
Zitierempfehlung
P Buggisch, YJ Horsmans, RS Brown, M Buti, K Agarwal, W Sievert, E Janczewska, C Hezode, M Rizzetto, R Parana, S De Meyer, R De Masi, D Luo, J Witek, S Zeuzem (2013) Safety and efficacy of twice daily versus every 8 hour telaprevir with Peginterfepon/Ribavirin (PR) in patients with cirrhosis. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0033-1352748
Mit CareLit weiterarbeiten